How Does Obesity Affect Longevity and Biological Aging?

The short answer

Obesity (BMI ≥30) is associated with a 5–10 year reduction in life expectancy for moderate obesity and up to 20 years for severe obesity (BMI ≥45). It increases the risk of cardiovascular disease, type 2 diabetes, at least 13 cancers, sleep apnoea, and osteoarthritis. Visceral adiposity — fat around the abdominal organs — is the most metabolically harmful form.

What the evidence actually shows

A 2014 study by Bhaskaran et al. in The Lancet, following 5.24 million UK adults, found a J-shaped relationship between BMI and mortality, with risk increasing steeply above a BMI of 25. A 2017 analysis in the NEJM, using pooled data from 239 prospective studies and 10.6 million participants, found that a BMI of 40–45 was associated with a 10-year reduction in life expectancy compared to a BMI of 22.5–25. Calle et al. (1999) in the NEJM demonstrated that obesity was associated with significantly higher cancer mortality, with the heaviest individuals having a 52% (men) and 62% (women) higher cancer death rate than those of normal weight. Visceral fat specifically drives insulin resistance, systemic inflammation (elevated IL-6, TNF-alpha, CRP), and dyslipidaemia.

"A BMI of 40–45 was associated with a 10-year reduction in life expectancy compared to a BMI of 22.5–25."

— GBD 2015 Obesity Collaborators, NEJM 2017

What the major health authorities say

MedlinePlus and the NIH identify obesity as a major risk factor for cardiovascular disease, type 2 diabetes, and cancer. The NIA recommends maintaining a healthy weight as a cornerstone of healthy ageing, noting that even modest weight loss (5–10% of body weight) produces meaningful improvements in blood pressure, blood glucose, and lipid profiles. The NIH National Heart, Lung, and Blood Institute recommends a combination of reduced calorie intake, increased physical activity, and behavioural strategies for weight management.

Practical implications

Even modest weight loss produces disproportionate health benefits: a 5% reduction in body weight reduces blood pressure, improves insulin sensitivity, and reduces inflammatory markers. The most evidence-supported approach to sustained weight loss combines caloric restriction (a 500–750 kcal/day deficit), increased physical activity (particularly resistance training to preserve muscle mass), and behavioural strategies. For individuals with BMI ≥30 and metabolic comorbidities, GLP-1 receptor agonists (semaglutide, tirzepatide) now have strong RCT evidence for both weight loss and cardiovascular risk reduction.

Where reasonable people still disagree

• The 'obesity paradox' — whether overweight or mildly obese older adults (BMI 25–30) have better survival than normal-weight individuals, and whether this reflects reverse causation.
• The optimal BMI target for older adults, where some evidence suggests that modest overweight may be protective against frailty and sarcopenia.
• Whether metabolically healthy obesity (normal metabolic markers despite high BMI) carries the same long-term mortality risk as metabolically unhealthy obesity.